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ABSTRACT
Hematopoietic stem cell transplantation (HSCT) is the only curative option for most children with severe com-
bined immunodeficiency disease (SCID). Survival for SCID followingHSCT has significantly improved over the
past several decades, and ranges from 70% to 95% depending on the clinical condition of the child at the time of
transplant, the availability of an HLA-matched sibling donor, and the SCID genotype/phenotype. In this article
we will review the types of SCID and discuss the critical HSCT issues that confront us today, including the op-
timal source of donor cells when an HLA-matched sibling is not available, as well as the pros and cons of using
conditioning therapy pretransplant. As SCID children have been followed for several decades, it is becoming ap-
parent that long-term outcome and durable T and B cell immune reconstitution are quite variable depending on
the initial treatment and source of donor cells. Finally, the development of methods to improve the early diag-
nosis of SCID along with designing prospective trials to evaluate the best approaches to curing these diseases
with minimal toxicity are critical to improving outcomes for children with SCID.
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Although early results using gene therapy for some
types of severe combined immunodeficiency diseases
(SCID) are encouraging [1,2], hematopoietic stem
cell transplantation (HSCT) remains the only curative
option for most children with SCID. There has been
a dramatic improvement in outcomes since the first
transplants were done about 40 years ago, mostly as
a result of significant advances in HLA typing, early
recognition and diagnosis, genotyping, detection,
and overall supportive care including detection and
treatment of opportunistic infections. Today, children
with SCID who are healthy at the time of transplant,
who are recipients of HLA-matched donor trans-
plants, and who do not require conditioning therapycan expect a better than 90% chance of long-term dis-
ease-free survival [2,3].
The major issues that confront us today involve
(1) the durability of the stem cell graft and subsequent
immune reconstitution, (2) donor selection when an
HLA-matched sibling is not available and the type,
and (3) intensity of conditioning regimens if one is
necessary. With respect to the latter, an additional
concern is potential long-term effects of conditioning
therapy on these very young infants. As newborn
screening for SCID becomes a reality, these issues
become even more critical. Virtually all of the
information that we have today regarding short-
and long-term outcomes for children with SCID
is the result of retrospective reports from either73
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CIBMTR). The need for prospective randomized
studies to evaluate some of these critical issues for
children with SCID is obvious.
SCID GENOTYPES AND PHENOTYPES
Many genetic mutations involving critical proteins
in DNA synthesis, T cell signaling, or V(D)J recombi-
nation have been identified as causing SCID [4]. These
mutations result in several distinct phenotypes based
upon the presence or absence of T, B, and NK cells.
The most common cause of SCID results from muta-
tions in the ILgc gene, and is seen in about 50% of all
SCID cases. Generally, these children have the
T2B1NK2 phenotype, and presumably, because of
the lack of NK cells, have durable T cell reconstitution
without any conditioning therapy [5].
It is estimated that 20% of SCID is associated with
the T2B2NK1 phenotype, most commonly seen with
a mutation in the RAG1 or RAG2 genes [6]. Another
group of patients with T2B2NK1 SCID is associated
with mutations in genes coding for proteins involved in
the nonhomologous DNA repair pathway, Artemis
and Ligase IV [7-9]. Cells from these patients show in-
creased sensitivity to ionizing radiation and alkylating
agents. There is a high incidence of SCID secondary to
a single point mutation in the gene that codes for Ar-
temis among Athabascan speaking Native Americans
in the Southwestern United States, in particular the
Navajo and Apache Indians [8]. At least 1 study sug-
gests that Navajo Indian children with SCID are par-
ticularly susceptible to treatment with alkylating
agents, especially with respect to subsequent growth
and development [10]. There is also at least 1 report
of children with Artemis mutations who presented
with EBV-related lymphomas, suggesting an increased
susceptibility to cancer in this patient population [11].
Interestingly, these patients had incomplete Artemis
mutations and a leaky SCID phenotype with some B
cells present.
The other SCID phenotypes (T2B1NK1 and
T2B2NK2) represent most of the remaining causes
with a variety of defects that include ADA and PNP de-
ficiency, IL7Ra defects, and defects in CD3d, e, and z,
among others. There remains a less well-characterized
group of SCID patients who present with T, B, and
NK cells. Some of these patients have leaky mutations
in genes such as RAG1/2 (Omenn’s syndrome), Arte-
mis, or ILgc; some are engrafted with maternal T cells,
whereas the rest have no identified genotype to date.
ENGRAFTMENT AND IMMUNE RECONSTITUTION
POST-HSCT
Because children with SCID have by definition ab-
sent to very low T cell immunity, it would be expectedthat they would be unlikely to reject a hematopoietic
stem cell graft. There are 3 conditions in which en-
graftment and reconstitution of at least T cell immu-
nity is likely to occur in this patient population even
without immunosuppressive conditioning therapy:
(1) when an HLA-matched related donor is available,
(2) when maternal cells have engrafted in utero, or
(3) when NK cells are absent. NK cells are thought
to play a major role in graft resistance in children
with SCID undergoing a haplocompatible transplant.
However, regardless of the SCID phenotype, stem
cells from HLA-matched sibling readily engraft with-
out conditioning.
There are, however, reports of a gradual loss of T
cell immunity based on thymic T cell receptor gene ex-
cision circle (TREC) output as well as T cell receptor
diversity in patients with SCID who have not received
conditioning [5,12]. This has led to some centers advo-
cating the use of ablative therapy for all children with
SCID undergoing a HSCT regardless of the pheno-
type or genotype. Of course, when unrelated donors
are used, either adult volunteers or umbilical cord
blood, ablative conditioning has generally been the
rule [3,13]. The situation is further complicated by
the fact that a subgroup of SCID patients have DNA
repair defects that make them particularly susceptible
to alkylating agents and ionizing radiation [10].
The paucity of data examining the late effects of condi-
tioning on this particular patient population, most of
whom are treated within the first year of life, further
complicates the debate over the optimal approach for
therapy.
ALTERNATIVE DONORS
When an HLA-matched related donor is not avail-
able there are 3 alternative sources that can be used:
a haplocompatible relative, HLA-matched unrelated
adult volunteer, or an unrelated banked UCB unit.
Although most of the experience with alternative do-
nors has been with haplocompatible relatives, there is
a growing use of unrelated donors, either adult vol-
unteers or cord blood [3,13,14]. There are advantages
and disadvantages to each alternative donor source
and unfortunately, because all of the reports to date
have been historic retrospective comparisons it is vir-
tually impossible to determine which approach might
be optimal. Almost all of the transplants using unre-
lated donors have employed either full myeloablative
or reduced intensity RIC regimens, whereas many of
the haplocompatible donor studies have not used
conditioning, at least as the initial transplant ap-
proach. This could certainly affect results of engraft-
ment efficiency, T and B cell reconstitution, and late
effects. The major concerns regarding the use of hap-
locompatible donors are the rejection rate, the rela-
tive delay in T cell recovery, and the loss of naı¨ve
HSCT for SCID 75T cells and normal thymopoiesis over time when
conditioning is not used. Newer technologies for
stem cell mobilization and efficient T cell depletion
(TCD) have resulted in the ability to administer
much larger doses of CD341 cells to SCID patients,
which could favorably impact at least some of these
issues.
CONDITIONING VERSUS NO CONDITIONING
The majority of children with SCID should not
theoretically need conditioning to overcome graft
resistance regardless of the HLA compatibility of
the donor; 50% have NK2 SCID and of those re-
maining, 30% to 40% are maternally engrafted, and
20% will have a matched sibling. For the remaining
children, engraftment without immunosuppressive
therapy may still be possible. For example, a perfectly
matched unrelated donor (10 of 10 allele match)
may engraft without conditioning just like a geno-
typic matched sibling [13]. In our own experience
(unpublished), using megadoses of haplocompatible
T cell-depleted CD341 PBSCs, about 40% of pa-
tients with NK1 SCID will engraft and reconstitute
T cell immunity.
The advantages of using no chemotherapy in
these children who are generally \6 months of age
are obvious; late effects on growth, development,
and organ function will be minimized. However, the
majority of recipients of HSCT who do not receive
any kind of myelosuppressive conditioning do not re-
constitute B cell immunity, and are required to be on
gammaglobulin therapy for the rest of their lives.
This in and of itself might be an acceptable trade-
off in terms of the toxic effects of chemotherapy.
However, the reports of incomplete T cell reconstitu-
tion in recipients of RIC transplants, compared to
those who receive myeloablation, with a gradual loss
of T cell immunity over time require us to consider
this approach more carefully [5,12]. Unfortunately,
there has been little correlation of these changes in
T cell immunity with clinical outcome, and it may
require longer follow-up to determine the exact
implications.
One way to address the toxic side effects of con-
ditioning in a young infant would be to do an initial
transplant without conditioning to restore T cell im-
munity, followed by a second transplant using the
same donor and ablative conditioning to establish
a B cell graft and durable T cell immunity once
the patient is older. Of course, this would not
work for unrelated cord blood transplants, and
would be logistically challenging when using unre-
lated volunteer donors. It is clear that what is needed
is a detailed long-term follow-up study of a large
number of children with SCID stratified by pheno-type, genotype, and donor source that compares
those who received conditioning (immunosuppres-
sive and/or myeloablative) to those who did not. Ide-
ally, this would be followed by a prospective study
that is designed based upon the results of the
retrospective analysis.
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disorders that are characterized by profound impair-
ment of T lymphocyte differentiation always associ-
ated with a direct or indirect deficiency in B cell
immunity. Consequently, in the absence of treatment,
patients are highly susceptible to infection and usually
die within the first year of life. Allogeneic hematopoi-
etic stem cell transplantation (HSCT) represents a life-
saving treatment of these conditions.
As discussed above, a unique aspect of HSCT in
SCID is that myeloablative conditioning is not re-
quired for donor cell engraftment. This situation of-
fers a significant clinical advantage, as toxicity of the
procedure can be reduced. This favorable setting also
led to the use of haploidentical parental HSCT for
the many SCID patients who do not have an HLA-
identical sibling. This development was made possible
by the availability of techniques allowing for depletion
of mature T cells from the graft.
The overall survival (OS) rate of SCID patients
who have undergone an HSCT from an HLA-identi-
cal sibling is good, being over 80% in patients treated
from 1968 until now [1,2]. With improvements in the
treatment of severe infection, the survival rate is over
90% since 1996 [1]. The survival rate of patients
treated by a haploidentical T cell-depleted (TCD)
HSCT is not as favorable with long-term survival
ranging from 50 to 78% [1,2]. Survival rates have,
however, increased over time from 35% survival in pa-
tients transplanted before 1985 to 75% in those treated
between 1996 and 1999 [1]. These superior outcomes
are because of, in large part, more effective prevention
and treatment of disease-related and procedure-re-
lated complications (infections and graft-versus-host
disease [GVHD]). Several parameters other than do-
nor availability play a role in determining survival:
age at diagnosis, clinical status at diagnosis, occurrence
of GVHD, graft rejection, and kinetics of T cell recon-
stitution. For example, patients transplanted during
the first 3.5 months of life have a better survival rate
compared to patients transplanted after that age, re-
gardless of the type of donor [2,3]. Despite TCD of
the graft in haploidentical HSCT, acute and chronic
GVHD (aGVHD, cGVHD) still significantly have
an impact on survival [1] . Graft rejection appears to
be an issue for patients with the NK1 type of SCID;
haploidentical HSCT is associated with an increasedrate of graft failure and a poorer prognosis for patients
with this SCID subset. It was recently shown that only
35% of NK1B2 SCID patients were long-term
survivors versus 60% of NK2B1 SCID patients [4].
Patterns of T cell reconstitution following HLA-
identical and haploidentical HSCT are very different,
and also affect outcomes. In HLA-identical HSCT,
the graft consists of progenitor cells as well as mature
T cells. Therefore, T cell reconstitution is bimodal,
with an early expansion of mature T cells followed
by a second wave of naive T cells, 3 to 4 months after
HSCT, that results from neothymopoiesis [3]. In hap-
loidentical HSCT, only selected hematopoeitic pro-
genitors are injected. Thus, the absence of early
mature T cell expansion results in a prolonged T cell
immunodeficiency during the 3 to 4 months post-
HSCT.
In the absence of myeloablative conditioning,
there is a split chimerism in most SCID patients
(.80%), with T cells and NK cells being of donor or-
igin in patients with a T2NK2 type of SCID [5]. All
other leukocyte subsets as well as hematopoietic line-
ages are of host origin. T cell progenitors, committed
pro-T cells, common lymphoid progenitors, multipo-
tent progenitors, or HSCs of donor origin migrate to
and colonize the thymus early after HSCT. A wave
of T cell differentiation ensues, which is sufficient to
(re)populate all T-lymphocyte niches and account for
the development of efficient T cell immune responses
[3,5,6]. There is, however, no engraftment of stem
cells in the bone marrow.
What are the consequences of the absence of stem
cell engrafment on long-term immune reconstitution?
This model predicts that after several years, the poten-
tial for T cell lymphopoiesis is exhausted, leaving the
patient with a given set of T cells for the remainder
of his/her life. This finding was first shown by Patel
et al. [7], by quantifying TRECs in circulating T cells
sequentially after HSCT. The presence of TRECs de-
notes that the T cells have not undergone division fol-
lowing TCR gene rearrangement, and thus detects
naı¨ve T cells. Such TREC1 T cells are no longer de-
tectable 10-12 years after HSCT performed in SCID
patients without myeloablative therapy [7]. There is
an alternative explanation for this unequivocal fall in
naı¨ve T cell counts: because the thymus in an SCID
patient developments in the absence of functional
HSCT for SCID 77T cell precursors, it might not be able to support thy-
mopoiesis as well as a healthy (non-SCID) thymus. In
addition, thymi in SCID patients may be further dam-
aged by infectious events or GVHD [8]. In our experi-
ence, the failure of secondary haploidentical HSCT to
improve T cell immunity, when performed several
years after the first HSCT, is consistent with the latter
hypothesis.
To further assess the significance of TREC1T cell
detection after HSCT in SCID patients, we have at-
tempted to correlate quantitation of TREC1 T cells
with chimerism [9]. Within a group of patients who re-
ceived HSCT.10 years ago, there is a strong correla-
tion between detection of TREC1 T cells and donor
myeloid chimerism; virtually no TREC1 T cells
were detected in the absence of myeloid donor chime-
rism, whereas TREC1 T cells were found, albeit in
variable numbers, in patients with evidence for donor
myeloid cells. Of note, we also found a correlation be-
tween the use of myeloablative conditioning regimen
and myeloid chimerism. These data strongly support
the concept that when donor myeloid cells are present,
as a marker of donor-derived hematopoiesis, thymo-
poiesis does persist, even if the thymus is not entirely
normal. Hence, it is possible that thymic function in
SCID patients is lost when donor progenitor cells,
which have emigrated to it, are exhausted. If true,
this concept implies that everything possible should
be done to maintain uninterrupted thymopoiesis in
treated SCID patients. Persistence of naı¨ve T cells
was also positively correlated with overall T cell recon-
stitution, and as expected, a strong correlation between
detection of TREC1 T cells and TCR repertoire di-
versity has been reported [10]. Finally, the occurrence
of GVHD [5], which likely impairs thymic function,
can also affect long-term T cell immune reconstitu-
tion. All of these indications point to a progression
of the immunodeficiency over time in transplanted
SCID patients in the absence of donor stem cell
engraftment.
Immunologic and clinical consequences of the de-
cline in thymopoiesis after HSCT in SCID patients
are significant. As shown in a recent survey of the
European registry, at last follow-up, 16% of SCID
patients transplanted with HSCT from an HLA-
identical donor and 18% of SCID patients trans-
planted with HSCT from an haploidentical parent
had a T cell immunodeficiency (defined as T cell lym-
phocytopenia (\1000/mL) or defective in vitro antigen
T cell proliferation) [1].
It is striking to note that NK cell reconstitution is
not as good as T cell reconstitution. This observation
has been made following both HSCT and gene ther-
apy, suggesting that the capacity for expansion of
NK cell precursors is reduced compared to T cells
[2]. It is presently unknown whether incomplete NK
cell reconstitution might have clinical consequences.By analyzing clinical manifestations of SCID patients
transplanted.10 years ago, the only significant differ-
ence observed between patients who originally had
NK2 SCID and those who had NK1 SCID is the
more frequent occurrence of chronic skin human pap-
illoma virus (HPV) disease [11]. NK2 SCID patients
exhibit a significantly lower NK cell count (median
45/mL) than NK1 SCID patients, 10 years or more af-
ter HSCT (median 178/mL). However, within the for-
mer group, patients with or without chronic human
papillomavirus (HPV) disease do not differ for NK
cell counts and function [11].
Another consequence of the lack of donor stem cell
engraftment is the typical absence of donor B cells. This
finding shows that B cell precursors contained in the
bone marrow inoculum have a limited capacity for dif-
ferentiation into multiple B cell clones and potentially
that B cells have a limited half-life. It is also possible
that competition with the host B cell lineage in B1
SCID or even pro-B cells in B2 SCID impairs donor
B cell differentiation. The frequently defective donor
B cell reconstitution therefore leads to persistent B
cell deficiency in a majority of patients [2,12]. These pa-
tients require long-term immunoglobulin replacement
therapy. This need is explained by either an absence of
host B cells (B2 SCID) or the presence of defective B
cells (B1 SCID caused by ILgc or JAK-3 mutations).
Although in the latter case, some B cell function can
be preserved [12,13], approximately 80% of patients
do require immunoglobulin replacement therapy. A
minority of SCID patients has long-lasting functional
B cell immunity associated with host B cells, and they
are mostly patients who had SCID with normal B cells
(IL-7Ra and CD3 deficiencies).
How can long-term immunity be improved in
SCID patients? Boost HSCT from an HLA-identical
sibling with coinfusion of mature T cells rapidly re-
stores immunity with clinical benefit. This effect is
much more unclear for patients transpanted with hap-
loidentical donors, given the risk of thymus inefficacy.
To avoid secondary loss of T cell responses, newly di-
agnosed SCID patients should be treated in a way so
that functional HSCs, those able to give rise to T lym-
phocytes (as well as NK and B lymphocytes) are pres-
ent or persist. Allogeneic HSCT preceded by
myeloablation to ensure donor stem cell engraftment
is an option. There are multiple examples of long-
term survival of SCID patients who received an
HSCT preceded by full myeloablation (high-dose bu-
sulfan and cyclophosphamide) and who have stable
functional T cells [1,14,15]. However, such an ap-
proach carries a very high risk of lethal toxicity in
HSCT recipients. It might thus be selectively used in
patients with mild or no infection and in NK1 SCID
patients who are at higher risk of graft failure. Gene
therapy, provided that early pluripotent progenitors
can be efficiently transduced is another option.
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Combined Immunodeficiency
Jennifer M. Puck
Pediatric Immunology Division, UCSF Children’s Hospital, San Francisco, CaliforniaInfants with SCID are healthy at birth, but die of
recurrent, severe infections in infancy unless they are
provided with a functional immune system [1,2].
HSCT and enzyme replacement (in the case of aden-
osine deaminase deficiency) have made this previ-
ously fatal set of diseases treatable [2-10]. Gene
therapy is also promising despite occurrences of leu-
kemia related to retroviral insertional mutagenesis in
1 early trial [11]. At least 15 genes have been identi-
fied that when mutated cause SCID; if a specific gene
defect has been defined in a family, prenatal or neo-
natal mutation diagnosis makes possible immediate
treatment. From such families we know that infants
treated before 3.5 months of age have better survival,
less morbidity, and lower treatment costs than those
recognized only after the onset of serious infections
[12,13]. Thus, SCID meets most of the criteria thathave been put forward for inclusion of new diseases
in universal newborn screening programs (Table 1)
[14]. SCID is fatal if untreated, and currently most
affected infants do not come to medical attention un-
til they develop opportunistic infections. Although
the precise incidence of SCID is not known, it is
estimated to be about 1/50,000 births, similar to
diseases such as galactosemia and biotinidase defi-
ciency, which are currently included in newborn
screening panels. Certain populations, such as In-
dians of Athabascan heritage, have an increased inci-
dence of autosomal recessive SCID, but all ethnicities
are at risk.
Definitive diagnosis and effective treatment of
SCID with HSCT are widely established. The best
outcome for SCID, as with many other conditions
for which newborn screening is now done, is
HSCT for SCID 79Table 1. Justifications for Universal Newborn Screening*
Proposed Screening Criteria How SCID Meets Criteria
Disease is serious SCID is fatal in first 1-2 years of life if untreated
Disease is not detectable by examination Newborns with SCID appear healthy
Incidence supports screening SCID incidence unknown, estimated to be around 1 in 50,000 births
Confirmative testing is well established Low absolute T cell count, negative mitogen proliferation in vitro
Effective treatment exists Allogeneic hematopoietic stem cell transplantation
Earlier treatment is better than delayed treatment Best survival and long-term outcome when treated before infections
occur
Diagnosis and treatment are available Pediatric immunologists, pediatric immunodeficiency transplantation
centers in every region
Screening is cost-effective An inexpensive, high-throughput screening test could save many lives
*Refs: Chan and Puck, 2005 [15]; Watson et al., 2006 [14].achieved if HSCT is performed very soon after birth,
ideally before clinical presentation with infections
and failure to thrive. Cost-effectiveness of screening
depends on development of an appropriate low-
cost, high-throughput screening test, preferably 1
that can be done with the dried blood spots currently
collected by all newborn screening programs. Chan
and Puck [15] published a successful dried blood
spot assay based on quantitating TRECs, which are
intracellular byproducts of successful T cell antigen
receptor rearrangement in the thymus. Absence of
TRECs can identify T-lymphocytopenic SCID in-
fants regardless of their genotype. A theoretical
cost-benefit analysis has supported SCID newborn
screening if a sufficiently inexpensive and accurate
test is used [16]. In addition to absence of TRECs,
high interleukin-7 (IL-7) levels could become an al-
ternative or second-tier maker for increasing specific-
ity of SCID detection [17].
A further impetus for SCID screening is the rec-
ommendation by public health authorities of vaccina-
tion programs that mandate use of live, attenuated
virus vaccines, such as the new multivalent antirotavi-
rus vaccine (given at 6 weeks of age), as well as live vac-
cines against varicella and measles-mumps-rubella.
These pose a danger to infants with SCID [18].
Through early diagnosis, newborn screening would
protect immunocompromised infants from potentially
severe disease by avoidance of exposure to vaccine-
strain viruses.
Although screening tests are designed to be sensi-
tive, so as not to miss true cases, specificity, or mini-
mizing false positive results, is also important to keep
programs affordable and maintain the trust of commu-
nity health providers. Plans are needed for patients
who will be screen positive and then have follow-up
studies that are not diagnostic for SCID, but are not
totally normal. The process of screening for T cell
lymphopenia, while intended to identify SCID, would
in addition identify complete DiGeorge syndrome and
perhaps other conditions.Current screening programs have networks of
metabolic disease specialists, hematologists, etc.,
throughout their states who are always available to
be contacted in addition to the primary care provider
[19]. The definitive diagnosis and treatment for
SCID will likewise require recruitment of clinical spe-
cialists to perform follow-up evaluations. A nationally
coordinated workup for all infants with results depos-
ited in a central databank would be a valuable resource
for assessing the performance of screening as well as
providing normative data and population-based rates
of abnormal immune parameters.
The present therapy of choice for SCID is alloge-
neic HSCT from an HLA-matched sibling. For infants
without a matched, related donor, alternative donors
and cell types are being used, including T cell-depleted
(TCD), haploidentical- related marrow or peripheral
blood stem cells (PBSC); matched unrelated donor
stem cells; and matched unrelated cord blood. Cur-
rently, experimental gene therapies are being refined
and may become widely available for SCID patients
in the future. Despite overall improving outcomes of
HSCT for SCID in many centers [8,20,21], questions
about optimal treatment remain to be worked out
with the aid of more complete data. There is no current
consensus regarding a single optimal HSCT protocol
for a very young, presymptomatic SCID infant without
an HLA-matched sibling donor. Delayed or incom-
plete immune reconstitution can leave patients requir-
ing lifelong intravenous immunoglobulin (IVIG),
remaining at risk for lethal viral infections, and having
poor nutritional status and autoimmunity. Sequellae of
chemotherapy include infertility; osteopenia; endo-
crine, renal, and pulmonary dysfunction; and impaired
tooth development. GVHD is not beneficial in HSCT
for SCID, and can lead to organ dysfunction and auto-
immunity. Collaborative studies based on information
in shared registries could be used to weigh these factors
and arrive at best practices for treatment of very young
presymptomatic infants with SCID to be identified by
newborn screening.
80 M. J. Cowan et al.In conclusion, SCID newborn screening is being
pursued with enthusiasm. By diagnosing SCID pre-
symptomatically, newborn screening is anticipated to
bring about early treatment to improve survival rates.
Test methodologies need optimizaton and screening
programs will need to be integrated with plans for de-
finitive diagnosis and management. Definition of the
true incidence of SCID, clarification of genetic versus
environmental contributions to phenotypes and dis-
covery of additional gene defects causing SCID are an-
ticipated.
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